Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine

Neuroscience Letters

Volumn 556, Issue , 2013, Pages 37-41

  Yamamori, Hidenaga ^a   Hashimoto, Ryota ^a,b   Ishima, Tamaki ^c   Kishi, Fukuko ^c   Yasuda, Yuka ^a   Ohi, Kazutaka ^a   Fujimoto, Michiko ^a   Umeda Yano, Satomi ^a   Ito, Akira ^a   Hashimoto, Kenji ^c   Takeda, Masatoshi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Brain derived neurotrophic factor (BDNF); Clozapine; Matrix metalloproteinase 9 (MMP 9); Treatment resistant schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; GELATINASE B;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ELISA KIT; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

BDNF; BRAIN-DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF); CLOZAPINE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, FOURTH EDITION; DSM-IV; MAJOR DEPRESSIVE DISORDER; MATRIX METALLOPROTEINASE-9; MATRIX METALLOPROTEINASE-9 (MMP-9); MDD; MMP-9; PANSS; POSITIVE AND NEGATIVE SYNDROME SCALE; TREATMENT-RESISTANT SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CLOZAPINE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROTEIN PRECURSORS; SCHIZOPHRENIA; TREATMENT FAILURE;

EID: 84887232834     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.09.059     Document Type: Article

References (23)

1. Chang S.H., Chiang S.Y., Chiu C.C., Tsai C.C., Tsai H.H., Huang C.Y., Hsu T.C., Tzang B.S. Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Res. 2011, 187:341-346.
2. Domenici E., Wille D.R., Tozzi F., Prokopenko I., Miller S., McKeown A., Brittain C., Rujescu D., Giegling I., Turck C.W., Holsboer F., Bullmore E.T., Middleton L., Merlo-Pich E., Alexander R.C., Muglia P. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE 2010, 5:e9166.
3. Ghosh A., Carnahan J., Greenberg M.E. Requirement for BDNF in activity-dependent survival of cortical neurons. Science 1994, 263:1618-1623.
4. Gorski J.A., Zeiler S.R., Tamowski S., Jones K.R. Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. J. Neurosci. 2003, 23:6856-6865.
5. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol. Psychiatry 2011, 16:960-972.
6. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J. Psychiatr. Res. 2007, 41:31-35.
7. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin. Neurosci. 2010, 64:341-357.
8. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog. Neurobiol. 2013, 100:15-29.
9. Hashimoto R., Moriguchi Y., Yamashita F., Mori T., Nemoto K., Okada T., Hori H., Noguchi H., Kunugi H., Ohnishi T. Dose-dependent effect of the Val66Met polymorphism of the brain-derived neurotrophic factor gene on memory-related hippocampal activity. Neurosci. Res. 2008, 61:360-367.
10. Lee B.H., Kim Y.K. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiology 2009, 59:51-58.
11. Martinowich K., Manji H., Lu B. New insights into BDNF function in depression and anxiety. Nat. Neurosci. 2007, 10:1089-1093.
12. Nagy V., Bozdagi O., Matynia A., Balcerzyk M., Okulski P., Dzwonek J., Costa R.M., Silva A.J., Kaczmarek L., Huntley G.W. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J. Neurosci. 2006, 26:1923-1934.
13. Nawa H., Takahashi M., Patterson P.H. Cytokine and growth factor involvement in schizophrenia - support for the developmental model. Mol. Psychiatry 2000, 5:594-603.
14. Park K.P., Rosell A., Foerch C., Xing C., Kim W.J., Lee S., Opdenakker G., Furie K.L., Lo E.H. Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke 2009, 40:2836-2842.
15. Pedrini M., Chendo I., Grande I., Lobato M.I., Belmonte-de-Abreu P.S., Lersch C., Walz J., Kauer-Sant'anna M., Kapczinski F., Gama C.S. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci. Lett. 2011, 491:207-210.
16. Pezawas L., Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., Egan M.F., Meyer-Lindenberg A., Weinberger D.R. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J. Neurosci. 2004, 24:10099-10102.
17. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2:24-32.
18. Rybakowski J.K. Matrix metalloproteinase-9 (MMP9) - a mediating enzyme in cardiovascular disease, cancer, and neuropsychiatric disorders. Cardiovasc. Psychiatry Neurol. 2009, 2009:904836.
19. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., Nakazato M., Watanabe H., Shinoda N., Okada S., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 2003, 54:70-75.
20. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci. Lett. 2003, 351:111-114.
21. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2003, 8:592-610.
22. Wong J., Hyde T.M., Cassano H.L., Deep-Soboslay A., Kleinman J.E., Weickert C.S. Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neuroscience 2010, 169:1071-1084.
23. Yoshida T., Ishikawa M., Niitsu T., Nakazato M., Watanabe H., Shiraishi T., Shiina A., Hashimoto T., Kanahara N., Hasegawa T., Enohara M., Kimura A., Iyo M., Hashimoto K. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS ONE 2012, 7:e42676.